Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CHRONASDAQ:ESLANASDAQ:KZRNASDAQ:SRZN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCHROChromocell Therapeutics$1.34+6.3%$10.97$4.50▼$38.00$8.69M3.6345,044 shs194,032 shsESLAEstrella Immunopharma$0.92+4.9%$1.00$0.63▼$3.23$33.42M0.36126,296 shs16,938 shsKZRKezar Life Sciences$4.56+1.6%$4.30$3.62▼$9.18$33.33M0.652,097 shs22,529 shsSRZNSurrozen$8.90+1.8%$8.80$5.90▼$18.17$76.17M0.5922,329 shs22,879 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCHROChromocell Therapeutics0.00%-88.45%-87.18%-89.92%-89.28%ESLAEstrella Immunopharma+4.88%-1.70%+10.76%+5.00%-19.65%KZRKezar Life Sciences+1.56%+6.79%+3.87%+10.68%-21.26%SRZNSurrozen+1.77%+6.53%+5.89%-19.06%-19.06%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCHROChromocell TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AESLAEstrella Immunopharma2.2514 of 5 stars3.53.00.00.00.01.70.0KZRKezar Life Sciences4.1799 of 5 stars3.23.00.04.60.63.30.6SRZNSurrozen2.4246 of 5 stars3.53.00.00.00.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCHROChromocell Therapeutics 0.00N/AN/AN/AESLAEstrella Immunopharma 3.00Buy$16.001,631.60% UpsideKZRKezar Life Sciences 2.33Hold$39.50766.23% UpsideSRZNSurrozen 3.00Buy$38.50332.83% UpsideCurrent Analyst Ratings BreakdownLatest CHRO, SRZN, ESLA, and KZR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025ESLAEstrella ImmunopharmaD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.005/12/2025SRZNSurrozenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCHROChromocell TherapeuticsN/AN/AN/AN/A($1.65) per shareN/AESLAEstrella ImmunopharmaN/AN/AN/AN/A$0.12 per shareN/AKZRKezar Life Sciences$7M4.76N/AN/A$16.02 per share0.28SRZNSurrozen$11.64M6.54N/AN/A($6.55) per share-1.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCHROChromocell Therapeutics-$7.38M-$1.24N/A∞N/AN/AN/A-453.90%N/AESLAEstrella Immunopharma-$7.31M-$0.26N/A∞N/AN/A-1,132.38%-273.91%N/AKZRKezar Life Sciences-$83.74M-$10.82N/AN/AN/AN/A-61.15%-50.27%8/12/2025 (Estimated)SRZNSurrozen-$63.56M-$24.96N/AN/AN/AN/A-842.90%-71.32%8/11/2025 (Estimated)Latest CHRO, SRZN, ESLA, and KZR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025KZRKezar Life Sciences-$2.56-$2.27+$0.29-$2.27N/AN/A5/9/2025Q1 2025SRZNSurrozen-$1.09-$3.13-$2.04-$7.43N/A$0.98 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCHROChromocell TherapeuticsN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/AKZRKezar Life SciencesN/AN/AN/AN/AN/ASRZNSurrozenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCHROChromocell TherapeuticsN/A0.600.60ESLAEstrella ImmunopharmaN/A0.220.22KZRKezar Life Sciences0.047.097.09SRZNSurrozenN/A10.0210.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCHROChromocell Therapeutics77.96%ESLAEstrella Immunopharma0.35%KZRKezar Life Sciences67.90%SRZNSurrozen66.57%Insider OwnershipCompanyInsider OwnershipCHROChromocell Therapeutics16.40%ESLAEstrella Immunopharma55.10%KZRKezar Life Sciences10.40%SRZNSurrozen45.18%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCHROChromocell Therapeutics46.49 million5.04 millionN/AESLAEstrella ImmunopharmaN/A36.17 million16.24 millionNot OptionableKZRKezar Life Sciences607.31 million6.55 millionNot OptionableSRZNSurrozen808.56 million4.69 millionNot OptionableCHRO, SRZN, ESLA, and KZR HeadlinesRecent News About These CompaniesWe Think Surrozen (NASDAQ:SRZN) Can Afford To Drive Business GrowthJuly 1 at 11:00 AM | finance.yahoo.comSurrozen (NASDAQ:SRZN) Shares Down 1.4% - What's Next?June 25, 2025 | marketbeat.comDown -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a TurnaroundMay 16, 2025 | zacks.comSurrozen secures patent for tissue repair technologyMay 15, 2025 | investing.comSurrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt PathwayMay 14, 2025 | globenewswire.comSurrozen, Inc.: Surrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 10, 2025 | finanznachrichten.deSurrozen Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | globenewswire.comSurrozen files to sell 5.21M shares of common stock for holdersApril 25, 2025 | markets.businessinsider.comSurrozen reports FY24 EPS ($21.67) vs. ($21.33) last yearApril 2, 2025 | markets.businessinsider.comInsiders Are Loving These 5 Tech and Biotech StocksApril 2, 2025 | 247wallst.comSurrozen Focuses on Ophthalmology Amid Financial ChallengesApril 1, 2025 | tipranks.comSurrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business UpdatesMarch 31, 2025 | globenewswire.comSurrozen, Inc. (NASDAQ:SRZN) Major Shareholder Group Gp Lp Column III Purchases 1,034,482 SharesMarch 29, 2025 | insidertrades.comSurrozen to focus Wnt expertise, technologies on ophthalmology programsMarch 27, 2025 | markets.businessinsider.comSurrozen to discontinue development of SZN-043 in alcohol associated hepatitisMarch 26, 2025 | markets.businessinsider.comSurrozen, Inc. Prioritizes Ophthalmology Pipeline with $175 Million Financing and Discontinues SZN-043 DevelopmentMarch 24, 2025 | quiverquant.comQSurrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye DiseasesMarch 24, 2025 | globenewswire.comSurrozen (NASDAQ:SRZN) Stock Quotes, Forecast and News SummaryJanuary 30, 2025 | benzinga.comHC Wainwright & Co. Initiates Coverage of Surrozen (SRZN) with Buy RecommendationJanuary 30, 2025 | msn.comH.C. Wainwright sets $32 target on Surrozen stock with Buy ratingJanuary 30, 2025 | msn.com(SRZN) Trading AdviceJanuary 30, 2025 | news.stocktradersdaily.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesTesla’s Robotaxi Hype Fuels Bullish Price Targets to $500By Sam Quirke | June 30, 2025View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?By Nathan Reiff | June 20, 2025View Rivian vs. Lucid: Who’s Best Positioned to Steal Tesla’s Thunder?Aeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionBy Dan Schmidt | July 2, 2025View Aeva & Mobileye: LiDAR Stocks Powering the Autonomous RevolutionTesla: The Next Month Could Make or Break the YearBy Sam Quirke | June 27, 2025View Tesla: The Next Month Could Make or Break the YearUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesCHRO, SRZN, ESLA, and KZR Company DescriptionsChromocell Therapeutics NYSE:CHRO$1.34 +0.08 (+6.35%) Closing price 07/1/2025 07:49 PM EasternExtended Trading$1.34 0.00 (0.00%) As of 07/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.Estrella Immunopharma NASDAQ:ESLA$0.92 +0.04 (+4.88%) Closing price 07/3/2025 03:38 PM EasternExtended Trading$0.86 -0.07 (-7.03%) As of 07/3/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.Kezar Life Sciences NASDAQ:KZR$4.56 +0.07 (+1.56%) As of 07/3/2025 01:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of tumors resistant to traditional chemotherapeutics. Kezar Life Sciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.Surrozen NASDAQ:SRZN$8.90 +0.16 (+1.77%) Closing price 07/3/2025 01:04 PM EasternExtended Trading$8.75 -0.14 (-1.62%) As of 07/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
